Alg2-cdg is a rare genetic condition that affects how the body adds sugars to proteins. People with Alg2-cdg often have feeding difficulties, low muscle tone, and developmental delays, and doctors may notice poor growth and low energy. It usually starts in infancy and is lifelong, but not everyone will have the same experience. Treatment focuses on supportive care like nutrition support, physical and speech therapy, and managing complications, and advances in care mean people often manage well with treatment. Severe forms of Alg2-cdg can lead to serious complications, but the outlook varies with the features and the level of supportive care.
Overview
Alg2-cdgSymptoms
Early features (sometimes described as early symptoms of ALG2‑CDG) include low muscle tone, weak suck and feeding problems, poor weight gain, and delayed milestones. Some have seizures, breathing or swallowing difficulties, eye movement problems, or liver issues. Severity varies widely.
Outlook and prognosis
Many living with Alg2-CDG grow and learn more slowly, and muscle weakness or feeding challenges may continue into childhood. Progress varies widely; some gain skills steadily with supportive therapies. Regular follow-up helps prevent complications and optimize comfort, nutrition, and mobility.
Causes and risk factors
Alg2-cdg stems from harmful changes in both ALG2 gene copies, typically inherited in an autosomal recessive way. Risk rises when both parents carry a variant, especially in consanguineous families; infections, poor nutrition, and stress may worsen severity, not cause it.
Genetic influences
Genetics is central to Alg2-cdg; it results from harmful changes in the ALG2 gene. Most cases are inherited in an autosomal recessive pattern. Different variants can influence severity and which body systems are most affected.
Diagnosis
Doctors suspect Alg2-cdg from clinical features and blood tests that point to a glycosylation problem. Genetic testing of the ALG2 gene confirms the diagnosis; imaging and organ checks may help. Ask about the genetic diagnosis of Alg2-cdg.
Treatment and drugs
Treatment for Alg2-CDG focuses on supportive care: managing low muscle tone, feeding and growth issues, seizures, liver and clotting problems, and developmental needs. Care teams often include neurology, gastroenterology, nutrition, physical and occupational therapy. Genetic counseling and coordinated follow-up help families plan ahead.
Symptoms
Alg2-cdg can touch many parts of the body, most noticeably muscles, movement, and feeding in infancy. Early on, this might look like a baby who feels floppy and tires during feeds, or a child who takes longer to sit, crawl, or walk. Early features of Alg2-cdg often include low muscle tone, weak suck, and slow weight gain, with learning and speech delays becoming clearer later on. Features can differ widely and may change over time.
Babies may feel floppy and need extra support for the head and trunk. Clinicians call this hypotonia, which means low muscle tone. It can make posture and balance harder.
Arms and legs can tire quickly with activity, so strength fades after repeated efforts. This may show up as slowing on stairs or needing more breaks during play. In Alg2-cdg, fatigue often improves a bit with short rests.
A weak suck and slow chewing can make breastfeeding or bottle feeds long and tiring. Reflux or gagging can happen with liquids. In Alg2-cdg, poor weight gain may follow without feeding supports.
Foods or drinks may go down the wrong way, leading to coughing or choking during meals. This can increase the chance of chest infections. Changing food textures and pacing can make swallowing safer.
How people usually first notice Alg2-cdg?
Families often first notice ALG2-CDG in infancy when a baby has poor muscle tone that feels “floppy,” trouble feeding, or is not gaining weight as expected. Doctors may pick up early red flags such as weak reflexes, delayed motor milestones, and unusual lab results like low blood sugar or abnormal liver tests, which prompt genetic testing to confirm the diagnosis. For many, the first signs of ALG2-CDG are recognized during the first year of life, though some features—such as developmental delays or frequent infections—become clearer as the child grows.
Types of Alg2-cdg
Alg2-CDG is a rare, genetic condition that affects how certain sugars are added to proteins, which can impact growth, movement, and organ function in different ways. People may notice different sets of symptoms depending on their situation. Researchers describe a few clinical variants rather than formal subtypes named by separate genes, and these variants reflect how early symptoms appear and how severe they become. When people search for types of Alg2-CDG, they’re usually referring to these recognized clinical patterns rather than distinct genetic branches.
Fetal–neonatal form
Symptoms start before birth or in the first weeks, often with poor muscle tone, feeding trouble, and breathing support needs. Babies may have small size, joint contractures, or unusual fat pads, and organ issues can occur. This form tends to be the most severe early on.
Infantile multisystem form
Signs emerge in the first year with low tone, delayed milestones, and poor weight gain. Liver enzymes, clotting tests, or hormone levels may be abnormal, and vision or heart findings can appear. Some children stabilize, but many need ongoing therapies across several organ systems.
Childhood neurological-predominant
Motor delay and coordination problems are most noticeable, with speech delay and learning differences. Growth and organ involvement may be milder than earlier-onset forms. Daily life often makes the differences between symptom types clearer.
Milder adolescent–adult form
Later onset with balance issues, neuropathy-like numbness or tingling, or slowly progressive weakness. Fatigue and subtle coordination changes may affect school, work, or sports, while organ tests can be near-normal. Not everyone will experience every type.
What genetics can tell you about symptoms
Certain ALG2 gene changes can lead to weak muscles, feeding trouble, floppy tone, and delayed milestones, while others bring seizures, vision or hearing issues, and breathing problems. These variations alter how well cells add sugar chains to proteins, which affects brain, muscle, and organ function.
Causes and risk factors
Alg2-cdg happens because of harmful changes in the ALG2 gene that disrupt how cells attach sugar chains to proteins. It is inherited in an autosomal recessive way, so a child is affected only if both parents carry a nonworking copy. When both parents are carriers, the risk of Alg2-cdg in each pregnancy is about 1 in 4, and close biological relatedness between parents can make carrier pairing more likely. Genes set the stage, but environment and lifestyle often decide how the story unfolds. Infections, other illnesses, and overall nutrition may influence how severe symptoms are or how often problems arise, but they do not cause the condition.
Environmental and biological risk factors
ALG2-CDG is present from birth and stems from internal biology set at or before conception. Doctors often group risks into internal (biological) and external (environmental). For this condition, environmental risk factors for ALG2-CDG are not well established, and known influences are mostly internal. Below are elements researchers consider when discussing how it can occur.
ALG2-CDG is present from birth based on internal biology set at or before conception. Birth events or delivery complications do not change whether a child has it.
Older paternal age slightly raises the chance of new changes that can arise in sperm across many conditions. For this condition, most cases do not seem to start this way, so any added effect is likely small.
No known link has been shown between radiation, heavy metals, or hormone-disrupting chemicals and ALG2-CDG. Avoiding harmful exposures during pregnancy remains good practice for overall fetal health.
Common infections during pregnancy have not been shown to increase the chance of this condition. Routine prenatal care and vaccination help lower other pregnancy risks.
Genetic risk factors
When both copies of the ALG2 gene carry harmful changes, the cell’s sugar-attachment process is disrupted, which can lead to Alg2-cdg. This condition follows an autosomal recessive pattern, meaning each parent is typically an unaffected carrier. In some cases, genetic testing can give a clearer picture of your personal risk. Understanding carrier status may help families plan ahead and watch for early symptoms of Alg2-cdg in siblings or future pregnancies.
ALG2 gene variants: Harmful changes in both copies of the ALG2 gene are the direct genetic cause of Alg2-cdg. These changes disrupt how cells attach sugar chains to many proteins. Severity can differ depending on which changes are present.
Autosomal recessive inheritance: A child is affected when they inherit one nonworking ALG2 copy from each parent. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of Alg2-cdg. Carriers usually have no symptoms.
Parental carrier status: Two carrier parents have a higher chance of having a child with the condition. Each child also has a 50% chance to be a carrier. Testing can clarify carrier status in parents and adult relatives.
Family history: Having a sibling or close relative with ALG2 changes increases the likelihood that other family members are carriers. Unaffected siblings often have a higher chance to be carriers even if they don’t have symptoms. This knowledge can guide testing and planning.
Blood-related parents: Parents who are related by blood have a higher chance of sharing the same rare ALG2 change. This raises the risk of Alg2-cdg in their children. Genetic counseling can help families understand these odds.
Shared ancestry: In small or isolated communities, the same rare gene changes can be more common across families. This can increase the chance that two carriers meet and have a child with the condition. Awareness can support informed family planning.
Variant type effects: Some ALG2 changes partly reduce the enzyme’s function, while others stop it almost completely. This can influence how early Alg2-cdg appears and how severe it is. Even within the same family, signs and severity can vary.
Sex-neutral risk: Because ALG2 sits on a non-sex chromosome, risk is similar for all sexes. Boys and girls can be affected when they inherit two altered copies. The chance depends on carrier status, not sex.
Lifestyle risk factors
Lifestyle habits do not cause Alg2-cdg, but they can meaningfully shape day-to-day function, symptom control, and risks of complications. Understanding how lifestyle affects Alg2-cdg helps families prioritize what matters most outside the clinic. The elements below highlight practical, condition-specific ways routine choices can help. These points reflect lifestyle risk factors for Alg2-cdg rather than genetics or environment.
Frequent, energy-dense meals can support growth and reduce fatigue from low reserves. Managing reflux and using safe-swallow strategies lowers aspiration and pneumonia risk.
Adequate protein and micronutrients help maintain muscle strength and immune resilience in the face of hypotonia and frequent infections. Dietitian-guided adjustments can address feeding intolerance and failure to thrive.
Consistent fluids support circulation and can reduce constipation that worsens discomfort and mobility limits. Extra hydration during illness may help prevent metabolic decompensation.
Regular, low-impact activity maintains muscle tone, posture, and joint range important for function in hypotonia. Avoiding overexertion and using pacing prevents prolonged fatigue and setbacks.
Risk prevention
Alg2-cdg is a genetic condition present from birth, so we can’t prevent it outright, but we can lower risks of complications and support long-term health. Prevention can mean both medical steps, like vaccines, and lifestyle steps, like exercise. Plans work best when they’re tailored to each person’s needs and adjusted over time. Partnering with a care team helps you decide what matters most right now and what to watch for next.
Staying up to date with routine vaccines reduces infections that can hit children and adults with Alg2-cdg harder. Ask about flu and pneumonia shots for the person and close family members.
Meeting with a genetics professional can explain recurrence risk and options for future pregnancies. This may include carrier testing and, if desired, prenatal or embryo testing to lower the chance of another child with Alg2-cdg.
Scheduled checks of growth, development, heart, liver, vision, and hearing can catch problems early. Knowing the early symptoms of Alg2-cdg helps prompt timely care and may prevent complications.
Early feeding support, such as high-calorie plans or thickened liquids if needed, helps prevent poor weight gain and aspiration. A dietitian can guide safe textures and supplements.
Transmission
Alg2-cdg is not contagious—it can’t be caught or spread through touch, food, or the air. It is a genetic condition that follows an autosomal recessive pattern: most children with Alg2-cdg inherit one nonworking copy of the same gene from each parent, who are usually healthy carriers. When both parents are carriers, each pregnancy has a 25% chance of a child with Alg2-cdg, a 50% chance of a carrier child, and a 25% chance of a child with two working copies. Rarely, a new gene change can be involved, but how Alg2-cdg is inherited is almost always through two carrier parents; a genetic counselor can explain the genetic transmission of Alg2-cdg and testing options.
When to test your genes
Consider genetic testing if you or a close relative has unexplained developmental delays, low muscle tone, growth issues, coagulation or liver abnormalities, or features suggesting a congenital disorder of glycosylation. Test before pregnancy or early in pregnancy for carrier screening. Re-test or expand panels if prior results were inconclusive.
Diagnosis
Alg2-cdg is typically identified by a mix of clinical clues and specialized lab tests, then confirmed with genetic testing. In many babies and children, patterns like low muscle tone, feeding difficulties, and unusual liver or clotting tests prompt doctors to look for a congenital disorder of glycosylation. Genetic testing may be offered to clarify risk or guide treatment. Early testing helps families and care teams plan care and monitor organs that can be affected.
Doctors usually begin by looking for a pattern of findings seen in congenital glycosylation disorders, such as low muscle tone, feeding issues, developmental delay, or liver and clotting changes. This pattern can point toward Alg2-cdg and guide which tests come next.
A careful family and health history can highlight similar issues in relatives and the timing of symptoms. This information helps narrow the list of possible conditions and supports targeted testing for Alg2-cdg.
A simple blood test checks sugar patterns on a transport protein called transferrin, often showing a "type I" CDG pattern. An abnormal result supports a CDG diagnosis but does not specify Alg2-cdg on its own.
More detailed analyses of sugar attachments on proteins can strengthen evidence for a CDG. These results, together with clinical features, can raise suspicion for Alg2-cdg while genetic testing provides confirmation.
Stages of Alg2-cdg
Alg2-cdg does not have defined progression stages. Symptoms and abilities can vary widely from child to child, and while some features may change over time, the condition doesn’t follow a predictable, step-by-step course. Doctors usually start with a conversation about your history and early symptoms of Alg2-cdg, then may order blood tests that look at how sugars attach to certain proteins and confirm the cause with genetic testing. Follow-up typically includes regular checks of growth, nutrition, movement, and seizures, along with periodic heart, liver, and eye evaluations.
Outlook and prognosis
Looking ahead can feel daunting, but most children with Alg2-cdg now survive into childhood and beyond, especially with early recognition and supportive care. Day to day, the outlook depends on how strongly the condition affects muscles, growth, feeding, and the liver. Some families first notice poor weight gain, low muscle tone, or delayed milestones; early symptoms of Alg2-cdg can guide which therapies to prioritize. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, including nutrition support, physical therapy, and prompt treatment of infections.
Severity varies. Some people experience milder movement or coordination challenges and attend mainstream school with supports, while others notice significant feeding difficulties, frequent infections, or developmental delays that require close, ongoing care. Serious complications can include breathing problems with illness, blood-clotting issues, and liver involvement; these raise medical risk and may affect life expectancy. Published reports suggest mortality is highest in infancy and early childhood for the most severe forms, often related to infections, organ failure, or clotting events, while children who pass those early years generally have a more stable course.
Over time, most people with Alg2-cdg benefit from a structured care plan that includes nutrition strategies, physical and occupational therapy, and monitoring for liver, heart, and clotting issues. Understanding the prognosis can guide planning and help you decide which supports to put in place at school and at home. Talk with your doctor about what your personal outlook might look like, including warning signs to watch for and how to handle them quickly. With ongoing care, many people maintain meaningful routines, celebrate steady gains, and navigate setbacks with a team that knows their goals.
Long-term effects
For many, Alg2-cdg affects movement, feeding, and learning over time, and some organs may need ongoing check-ins. Long-term effects vary widely, and the mix and intensity can look very different from one person to the next. While early symptoms of Alg2-cdg often show up in infancy, the long-term picture depends on which body systems are most involved.
Low muscle tone and delayed milestones often persist into later childhood. Walking may be late or need support such as braces or a wheelchair. Balance and coordination can remain challenging.
Cognitive abilities range from mild to more significant disability. Speech may be delayed, and some rely on alternative ways to communicate. Everyday learning often improves slowly over years.
Some develop epilepsy that can come and go or change with age. Seizure types vary, and episodes may cluster during illnesses. Over time, patterns can stabilize or shift.
Feeding difficulties and reflux are common and can affect weight gain. Some need tube feeding to meet nutrition needs. Stature may be smaller than peers.
How is it to live with Alg2-cdg?
Living with ALG2-CDG often means juggling fatigue, low muscle tone, and coordination challenges alongside frequent medical visits to monitor growth, feeding, liver, heart, and neurologic health. Daily life can involve therapies—physical, occupational, speech—adaptive equipment for mobility or feeding, and careful planning around illnesses because recovery can be slower and setbacks more noticeable. For families and caregivers, the learning curve is steep and schedules can be crowded, but clear care plans, early intervention, and supportive communities help share the load and celebrate progress. Many find that balancing realistic expectations with consistent support allows children and adults with ALG2-CDG to participate in school, social life, and family routines in meaningful ways.
Treatment and drugs
Alg2-CDG treatment focuses on easing symptoms, preventing complications, and supporting growth and development, since there’s currently no cure targeting the root cause. Care is typically coordinated by a metabolic or genetics team and may include nutrition support (high-calorie feeds, gastrostomy when needed), physical and occupational therapy to build strength and skills, and speech therapy for feeding and communication. Doctors may use seizure medicines, reflux treatment, and tailored plans for low muscle tone or movement issues; a doctor may adjust your dose to balance benefits and side effects. Regular checks often cover heart, liver, vision, and clotting, with prompt treatment of infections and careful hospital support during illnesses or surgeries. Supportive care can make a real difference in how you feel day to day, and clinical trials or registries may be options to stay connected with emerging therapies for Alg2-CDG.
Non-drug treatment
Life with Alg2-cdg often involves extra support for movement, feeding, and communication to make daily routines easier. Non-drug treatments often lay the foundation for comfort, safety, and learning alongside any medical care. Getting these supports in place early can help address early symptoms of Alg2-cdg and reduce stress for families.
A lead clinician or nurse helps organize appointments and therapies. Clear plans reduce repeated tests and make day-to-day decisions simpler.
A dietitian adjusts calories, textures, and timing to support growth and energy. This can include higher-calorie meals or specialized formulas.
A speech or occupational therapist works on safe swallowing and more efficient eating. Techniques like pacing, positioning, and texture changes can cut choking risk and mealtime fatigue.
If oral intake is not enough, a nasogastric or gastrostomy tube can provide nutrition. Training helps families handle daily care, prevent skin irritation, and keep feeds comfortable.
Your genes may have an impact on how drugs work for you
Some medicines are processed differently in people with ALG2-CDG because gene changes can alter liver enzymes and cell glycosylation, affecting how drugs move, work, and clear. Clinicians often adjust choices or doses and monitor closely to balance benefits and side effects.
Pharmacological treatments
There’s no single drug that treats Alg2-cdg itself, so medicines focus on easing day-to-day symptoms like seizures, reflux, and feeding or heart issues. Choices depend on age, severity, and the specific features a child or adult is living with, including early symptoms of Alg2-cdg such as low muscle tone or feeding difficulties. Treatment plans are usually adjusted over time as needs change. Not everyone responds to the same medication in the same way.
Levetiracetam or valproate are common first choices for epilepsy; topiramate or clobazam may be added if seizures persist. Regular blood tests may be needed with valproate, and dosages are tailored to seizure pattern and side effects. Rescue medicines like intranasal midazolam or diazepam can help stop prolonged seizures.
Baclofen can relax tight muscles and ease stiffness; tizanidine or diazepam may be alternatives. Drowsiness and weakness can occur, so dosing is adjusted slowly to balance benefit and side effects.
If a cardiomyopathy or heart weakness is present, enalapril (an ACE inhibitor) or carvedilol (a beta‑blocker) may support heart pumping. Diuretics like furosemide can reduce fluid buildup and ease breathing.
Omeprazole (a proton pump inhibitor) or famotidine (an H2 blocker) can lessen acid reflux and protect the esophagus. This may improve comfort, appetite, and weight gain when reflux is frequent.
Genetic influences
Alg2-cdg stems from harmful changes in the ALG2 gene, which helps cells add sugar chains to many proteins (glycosylation). These gene changes lower or disrupt glycosylation, which is why Alg2-cdg can affect several organs, from muscles to the nervous system. If you’re wondering how Alg2-cdg is inherited, it follows an autosomal recessive pattern: a child must receive two nonworking copies of ALG2, one from each parent. Parents are usually healthy carriers, and when both carry an ALG2 change, each pregnancy has a 25% chance of Alg2-cdg, a 50% chance the child will be a carrier, and a 25% chance of neither. Symptoms and severity can vary widely, even among siblings with the same ALG2 changes. DNA testing can sometimes identify these changes.
Is Alg2-cdg genetic?
Genetics is central to Alg2-cdg; it results from harmful changes in the ALG2 gene. Most cases are inherited in an autosomal recessive pattern. Different variants can influence severity and which body systems are most affected.
Pharmacogenetics—how genetics influence drug effects
Treatment in ALG2‑CDG is mostly supportive, so genetics shape care in two ways: the disease‑causing ALG2 changes and the separate, common gene differences that affect how you respond to medicines. ALG2 variants don’t directly change the liver enzymes that break down most drugs, but ALG2‑CDG can involve liver and clotting issues, so doctors often choose drug types and doses with extra caution and monitor more closely. Genetic testing can sometimes identify how your body handles certain medicines, such as some anti‑seizure drugs, which can help fine‑tune dosing or point to alternatives. This is especially relevant because many people with ALG2‑CDG need seizure control, nutrition support, or treatments for reflux or infections, and common drug‑response genes can influence how well those medicines work or what side effects you might have.
Because ALG2‑CDG may affect the liver and clotting system, clinicians often avoid medicines that stress the liver or raise bleeding risk, and they may check drug levels or blood tests more often than usual. There isn’t a gene‑targeted therapy yet for ALG2‑CDG, so pharmacogenetic testing for ALG2‑CDG mainly guides safer, more effective use of supportive medicines rather than treating the root cause.
Interactions with other conditions
Colds, flu, or other infections can hit harder in Alg2-cdg because low muscle tone and feeding or breathing challenges may already be present, so an illness can tip things toward dehydration or hospital care. A condition may “exacerbate” (make worse) symptoms of another, so reflux or swallowing problems can increase the risk of chest infections, while chest infections can in turn worsen fatigue and weakness. Epilepsy, heart rhythm or muscle problems, and liver involvement sometimes occur alongside Alg2-cdg, and these can interact—for example, seizure medicines that rely on liver processing may need closer monitoring if liver tests change, and heart issues can affect which medications are safest. Surgery or anesthesia require extra planning because some people with Alg2-cdg have bleeding or clotting differences and may be more sensitive to breathing complications. Early symptoms of Alg2-cdg can overlap with other rare metabolic or neuromuscular conditions, so coordinated care helps avoid conflicting treatments. With careful care, many people live well despite having both Alg2-cdg and other health issues, and shared care plans between neurology, cardiology, gastroenterology, and genetics can reduce risks during illnesses or procedures.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns that puzzled them: infants who seemed unusually weak, children who didn’t gain skills as expected, or recurrent illnesses that doctors couldn’t neatly explain. Decades ago, these stories were recorded under broad labels like “congenital disorders of glycosylation” because the shared thread—trouble attaching sugar chains to proteins—was only beginning to come into focus.
First described in the medical literature as part of the early CDG group in the late 1990s, Alg2‑CDG was initially hidden within a cluster of similar conditions. Clinicians recognized features such as low muscle tone, feeding difficulties, growth concerns, and infections, but the exact type was hard to pinpoint without advanced testing. As newborn screening and metabolic evaluations improved, patterns emerged that suggested different CDG subtypes, including those tied to specific steps in building sugar chains.
From these first observations, researchers began mapping the cellular assembly line that builds these sugars. ALG2, a gene that helps add early pieces to a growing sugar chain, drew attention when changes in it were linked to the symptoms families had been reporting. Once DNA sequencing became more widely available in the 2000s and 2010s, individual case reports turned into small series from different countries, confirming that Alg2‑CDG appears across many populations and can vary in severity.
Over time, descriptions became more detailed. Reports broadened from infancy into childhood and, in a few cases, adolescence, showing that Alg2‑CDG can affect movement, development, and the immune system to different degrees. Lab tests that look at the “sugar coating” on blood proteins helped doctors suspect a CDG, while gene testing clarified when ALG2 was the cause. This shift—from recognizing a pattern to identifying a precise gene change—allowed families to receive clearer answers and connect with others facing the same diagnosis.
In recent decades, knowledge has built on a long tradition of observation. Registries and international collaborations gathered health histories, early symptoms of Alg2‑CDG, and long‑term outcomes to guide care. While treatments remain supportive, earlier recognition has improved monitoring for infections, nutrition, and physical therapy, and has given families a name for what they had long noticed.
Despite evolving definitions, the history of Alg2‑CDG reflects steady progress: community stories prompting clinical attention, careful bedside observations shaping lab studies, and genetics tying it all together. Each step has refined how Alg2‑CDG is understood today and laid the groundwork for future research.